Edition:
United States

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

68.38USD
4:00pm EDT
Change (% chg)

$0.11 (+0.16%)
Prev Close
$68.27
Open
$68.39
Day's High
$68.60
Day's Low
$67.68
Volume
495,824
Avg. Vol
120,494
52-wk High
$70.06
52-wk Low
$25.87

Chart for

About

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $2,597.98
Shares Outstanding(Mil.): 37.46
Dividend: --
Yield (%): --

Financials

  QDEL.OQ Industry Sector
P/E (TTM): 349.48 37.70 33.54
EPS (TTM): 0.20 -- --
ROI: 2.20 8.01 13.09
ROE: 4.18 11.90 15.10

BRIEF-Quidel Reports Q1 Non-GAAP Earnings Per Share $1.29

* Q1 REVENUE $169.1 MILLION VERSUS I/B/E/S VIEW $150.9 MILLION

May 08 2018

BRIEF-Quidel Corp Says Increased Size Of Board To Eight Members - SEC Filing

* QUIDEL CORP SAYS INCREASED SIZE OF COMPANY'S BOARD OF DIRECTORS TO EIGHT MEMBERS - SEC FILING Source text (https://bit.ly/2q4dLBG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 04 2018

BRIEF-Quidel Receives FDA Clearance For Its Instrument

* QUIDEL RECEIVES FDA CLEARANCE FOR ITS POINT-OF-CARE SOFIA® LYME FLUORESCENT IMMUNOASSAY FOR USE WITH SOFIA® 2 INSTRUMENT Source text for Eikon: Further company coverage:

Mar 05 2018

BRIEF-Quidel Q4 Non-Gaap Earnings Per Share $0.56

* QUIDEL REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 21 2018

BRIEF-Quidel Receives 510(K) Clearance For Quickvue Influenza A+B Test

* QUIDEL RECEIVES 510(K) CLEARANCE FOR QUICKVUE INFLUENZA A+B TEST, ASSAY MEETS FDA'S CLASS II RIDT REQUIREMENTS

Feb 13 2018

Competitors

Earnings vs. Estimates